ARCHIVES

Second-Generation CML Drugs Show Promise For Frontline

This article is from The Cancer Letter archive.

Vol. 31 No. 12 | December 26, 2008

Download PDF Visit The Full Archive

Related Articles

Afinitor Significantly Reduced Tumor Size In TSC-Related Renal Angiomyolipomas

January 25, 2013

Cancer Deaths In Black Men Could Drop By Cutting Tobacco

April 30, 2004

NCI Intramural Programs: Clinical Trials Support System Need Attention, report Advises DCS

December 19, 1997

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

September 8, 2006

Study: BRCA2-Negative Women Could Still Have High Risk

December 27, 2013

Response From Center Representatives In L.A. To NCI Questions Is “Frusterating,” DeVita Says

April 13, 1984